Kura Oncology, Inc. (NASDAQ:KURA) Insider Mollie Leoni Sells 4,963 Shares

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Kura Oncology Trading Down 1.5 %

Shares of NASDAQ:KURA traded down $0.12 during trading on Friday, hitting $7.91. The company had a trading volume of 1,362,535 shares, compared to its average volume of 1,345,422. The stock has a market cap of $615.08 million, a price-to-earnings ratio of -3.35 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a fifty day simple moving average of $8.97 and a two-hundred day simple moving average of $15.42. Kura Oncology, Inc. has a one year low of $6.98 and a one year high of $24.17.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.01. During the same period in the prior year, the company earned ($0.50) earnings per share. As a group, equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KURA shares. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research report on Wednesday, January 8th. Wedbush reiterated an "outperform" rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Monday, November 4th. JMP Securities reissued a "market outperform" rating and set a $32.00 price objective on shares of Kura Oncology in a report on Tuesday, November 19th. Lifesci Capital raised Kura Oncology to a "strong-buy" rating in a report on Tuesday, October 22nd. Finally, UBS Group assumed coverage on Kura Oncology in a research report on Thursday, October 24th. They issued a "buy" rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $27.38.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently made changes to their positions in the company. Hsbc Holdings PLC lifted its stake in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company's stock worth $374,000 after purchasing an additional 2,167 shares during the last quarter. Marshall Wace LLP purchased a new position in Kura Oncology during the 2nd quarter valued at $541,000. AQR Capital Management LLC grew its position in Kura Oncology by 251.5% in the 2nd quarter. AQR Capital Management LLC now owns 81,655 shares of the company's stock valued at $1,681,000 after acquiring an additional 58,422 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in Kura Oncology by 5.4% in the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company's stock worth $793,000 after purchasing an additional 1,976 shares during the period. Finally, Quarry LP purchased a new position in Kura Oncology in the 2nd quarter worth about $196,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.